{"id":16524,"date":"2023-06-19T11:14:28","date_gmt":"2023-06-19T09:14:28","guid":{"rendered":"http:\/\/161.116.26.48\/?page_id=16524"},"modified":"2024-12-04T14:53:50","modified_gmt":"2024-12-04T12:53:50","slug":"lipid-nanoparticles-for-the-treatment-of-dry-eye-disease","status":"publish","type":"page","link":"https:\/\/www.fbg.ub.edu\/es\/que-hacemos\/tecnologias-materiales-y-licencias\/tecnologias-para-licenciar\/lipid-nanoparticles-for-the-treatment-of-dry-eye-disease\/","title":{"rendered":"Nanotechnological eyedrops for glaucoma, dry eye and ocular inflammation"},"content":{"rendered":"<h3>Problem addressed by the project<\/h3>\n<p>Nanotechnological eyedrops are focused on <strong>glaucoma<\/strong> and associated dry eye and ocular inflammation. Glaucoma total annual costs to NHS in Spain account for \u20ac10 million. Our product will significantly decrease this burden.<br \/>\nIn Spain, 728,893 patients diagnosed with glaucoma and 25% of them not-adhere to treatment (182,224 patients).<br \/>\nMoreover, 50% of the patients experience side effects with current treatments, which are <strong>dry eye<\/strong> and <strong>ocular inflammation<\/strong>. Also, no current medication addresses neuroprotection.<br \/>\nAddressing neuroprotection and overcoming adverse effects may increase adherence rates, extend surgery timespan and increase quality of life for glaucoma patients.<\/p>\n<h3>G<strong>laucoma market<\/strong><\/h3>\n<p>It is estimated that by 2040, <strong>22 million people will suffer vision loss due to glaucoma<\/strong>.<br \/>\n<strong>Medication discontinuation rates are alarmingly high (25%), <\/strong>mainly due to non adherence.<br \/>\n<strong>Current medications cause adverse effects, do not exert neuroprotection and 15% of patients end up having surgery after 5 years of diagnosis.<\/strong><\/p>\n<p>There is an <strong>unmet medical need<\/strong> for:<\/p>\n<ul>\n<li>Development of <strong>neuroprotectant agents to overcome glaucoma progression.<\/strong><\/li>\n<li><strong>Overcome dry eye and ocular inflammation<\/strong> adverse effects of current medications increasing drug adherence.<\/li>\n<\/ul>\n<h3>Product<\/h3>\n<p><strong>Ophthalmic eyedrops classified as medical device formed by second-generation nanostructured lipid carriers (NLCs) containing natural compounds<\/strong> offering:<\/p>\n<ul>\n<li>Retinal and optic nerve neuroprotection effective for glaucoma<\/li>\n<li>Reversion of marketed medication side-effects<br \/>\n&#8211; Therapeutically effective against dry eye<br \/>\n&#8211; Anti-inflammatory<\/li>\n<\/ul>\n<h3><strong>Project publications<\/strong><\/h3>\n<p>Int J Pharm . 2024 May 11:658:124222.<br \/>\ndoi: 10.1016\/j.ijpharm.2024.124222<\/p>\n<p>Int J Nanomedicine . 2023 Nov<br \/>\n23:18:6979 6997. doi: 10.2147\/IJN.S429565<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Problem addressed by the project Nanotechnological eyedrops are focused on glaucoma and associated dry eye and ocular inflammation. Glaucoma total&#8230;<\/p>\n","protected":false},"author":2,"featured_media":20773,"parent":1399,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-tecnologies.php","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-16524","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/pages\/16524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=16524"}],"version-history":[{"count":7,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/pages\/16524\/revisions"}],"predecessor-version":[{"id":20786,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/pages\/16524\/revisions\/20786"}],"up":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/pages\/1399"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/media\/20773"}],"wp:attachment":[{"href":"https:\/\/www.fbg.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=16524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}